Beck Mack & Oliver LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 371,850 shares of the biopharmaceutical company’s stock after selling 30,642 shares during the period. Beck Mack & Oliver LLC’s holdings in Gilead Sciences were worth $23,259,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of GILD. Advisors Preferred LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth about $31,000. Legacy Financial Advisors Inc. boosted its stake in shares of Gilead Sciences by 361.3% during the 4th quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 383 shares during the last quarter. We Are One Seven LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth about $37,000. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Gilead Sciences by 56.9% during the 4th quarter. Jackson Grant Investment Advisers Inc. now owns 717 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 260 shares during the last quarter. Finally, Baldwin Brothers Inc. MA boosted its stake in shares of Gilead Sciences by 47.2% during the 4th quarter. Baldwin Brothers Inc. MA now owns 808 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 259 shares during the last quarter. 80.03% of the stock is currently owned by hedge funds and other institutional investors.

In related news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $71.20, for a total value of $3,560,000.00. Following the transaction, the director now owns 2,877,762 shares in the company, valued at $204,896,654.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.16% of the company’s stock.

Shares of GILD stock opened at $67.59 on Friday. The stock has a market cap of $85.86 billion, a PE ratio of 10.99, a P/E/G ratio of 4.15 and a beta of 1.19. Gilead Sciences, Inc. has a 1-year low of $60.32 and a 1-year high of $82.71. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.29 and a current ratio of 3.36.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The company’s revenue was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.78 earnings per share. Analysts forecast that Gilead Sciences, Inc. will post 6.23 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Investors of record on Friday, March 15th will be issued a $0.63 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date of this dividend is Thursday, March 14th. This represents a $2.52 annualized dividend and a yield of 3.73%. Gilead Sciences’s dividend payout ratio (DPR) is presently 37.07%.

Several research firms have issued reports on GILD. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 1st. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, November 8th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, November 14th. Oppenheimer reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, November 14th. Finally, Citigroup reaffirmed a “buy” rating and set a $100.00 price target on shares of Gilead Sciences in a research note on Tuesday, February 5th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $84.01.

TRADEMARK VIOLATION NOTICE: “Beck Mack & Oliver LLC Lowers Position in Gilead Sciences, Inc. (GILD)” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/beck-mack-oliver-llc-lowers-position-in-gilead-sciences-inc-gild/2825060.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Tariff

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.